DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Uterine Fibroid Treatment Market - Forecast (2016-2022)" report to their offering.
Uterine fibroid is a type of tumour that grows in the muscular wall of the uterus. It occurs mainly in about 20%-40% in women during their reproductive ages. Globally, development of efficient and advanced technology, rise in the awareness among people regarding diseases, increasing government initiatives across the globe, growing prevalence of uterine fibroids and change in lifestyle mainly dietary pattern, and rising number of women of reproductive age (WRA) across the globe are the prime growth drivers of the uterine fibroid treatment market.
In addition, an increase in adoption of uterine fibroid treatment in emerging economies such as China, India and others, will create new opportunities for the uterine fibroid treatment market. However, higher cost of research and development are the key restraints for the uterine fibroid treatment market.
Geographically, North America dominated the uterine fibroid treatment market, because of higher number of patients suffering from uterine fibroid problem (20 million women in North America), high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing women population, rise in awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the types, intramural fibroids has the highest market share in the uterine fibroid treatment market.
Key Topics Covered:
1. Market Overview
2. Executive Summary
3. Market Landscape
4. Market Forces
5. Strategic Analysis
6. Uterine Fibroid Treatment Market, By Type
7. Uterine Fibroid Treatment Market, By Treatment
8. Uterine Fibroid Treatment Market, By Geography
9. Uterine Fibroid Treatment Entropy
10. Company Profiles
- F. Hoffmann-La Roche Ltd
- Boston Scientific Corporation
- Richard Wolf Medical Instruments
- Eli Lilly and Company
- GlaxoSmithKline Pharmaceuticals Limited
- Bayer AG
- Pfizer Inc.
- Johnson & Johnson
- Novartis AG
Siemens Medical Solutions
For more information about this report visit http://www.researchandmarkets.com/research/qq2ktl/uterine_fibroid